Neumora Therapeutics, Inc. (NMRA) Tops Q4 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Guggenheim Reiterates Buy Rating on Neumora Therapeutics (NMRA), PT $7
March 3, 2025 1:15 PM ESTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $7.00 price target on Neumora Therapeutics (NASDAQ: NMRA)
The analyst comments "Key Message: Today NMRA reported 4Q24 financial results and pipeline updates. Our key highlights include: (1) NMRA has paused KOASTAL-2 and -3 studies of navacaprant (KOR antagonist) and plans to resume them in March 2025 after implementing a series of optimizations based on learnings from KOASTAL-1 (K-1; recall this study failed the primary endpoint - see HERE and HERE), including enhanced... More
Neumora Therapeutics (NMRA) PT Lowered to $6 at Stifel
March 3, 2025 9:16 AM ESTStifel analyst Paul Matteis lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $6.00 (from $26.00) while maintaining a Buy rating.
The analyst comments "We remain Buy rated on NMRA, as we think the risk/reward on the KOSTAL-2/3 trials is... More
